Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ).
Ab&B Bio-Tech CO., LTD. JS plans to abolish its Supervisory Committee and transfer its statutory oversight functions to the Board’s Audit Committee, a move that aligns the company’s governance structure with its operational needs and the latest requirements of PRC company law. The change would also terminate existing supervisor positions and streamline internal oversight processes, subject to shareholder approval at a forthcoming general meeting.
The company will amend its Articles of Association to reflect the removal of the Supervisory Committee, update provisions in line with new regulatory standards, and perform textual and structural clean-up. In parallel, Ab&B Bio-Tech has reconstituted its Strategy Committee, appointing chairman An Youcai alongside members He Yiming and Li Xiangming, signaling a refreshed strategic governance framework at board level.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a mainland China-based joint stock company listed in Hong Kong, operating in the biotechnology sector. Through its group structure, it focuses on bio-tech products and related services, positioning itself within the broader life sciences and healthcare supply chain in the Chinese and regional markets.
Average Trading Volume: 740,312
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.54B
Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.